Scientific deep-dive

Retatrutide Regulatory Status & Sourcing Guide (Pre-Approval)

No FDA-approved retatrutide brand exists. Compounded retatrutide sits in a §503A gray zone: not on the FDA shortage list, bulk API not in any approved drug. Lilly plans an FDA filing in Q1 2027. Red flags, §503A rules, and the semaglutide enforcement precedent.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·16 citations

The honest answer to “where can I buy retatrutide” in October 2026 is: you can't buy an FDA-approved retatrutide brand product, because there isn't one yet. If you arrived searching for “GLP-3,” that is a nickname for this same molecule and not a separate drug — see what GLP-3 actually means. Eli Lilly's investigational triple agonist (internal code LY3437943) has reported phase 3 results from TRIUMPH-4 (December 11, 2025)[7] and published TRIUMPH-1 (NEJM) and TRIUMPH-2 (Lancet) in 2026[12][13]. Lilly's August 2026 earnings release says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027[14], so no FDA approval is possible in 2026. A small compounded retatrutide market does exist, but it sits in a regulatory gray zone that is meaningfully different from the compounded-semaglutide shortage pathway the FDA enforced against and closed in 2026 — retatrutide is not, and has never been, on the FDA Drug Shortages list, because the reference brand doesn't exist to be in shortage in the first place[5]. This article walks through what is and isn't legally on the table, the §503A compounding rules that apply, the precedent set by compounded semaglutide, and the red flags any patient should evaluate before considering a purchase from any provider claiming to sell retatrutide. For the peer-reviewed efficacy data and mechanism, see our companion retatrutide triple-agonist evidence review.

Safety notice

Compounded medications are not FDA-approved. Bulk-API sourcing for retatrutide is not currently authorized under the standard §503A compounded-shortage pathway, because there is no FDA-approved reference product and retatrutide is not on the FDA Drug Shortages list. Discuss any retatrutide purchase decision with a licensed clinician before proceeding.

The honest short answer

There is no FDA-approved retatrutide brand product as of October 2026. The molecule is in late-stage clinical development — phase 3 TRIUMPH-4 in adults with knee osteoarthritis and obesity read out on December 11, 2025 with up to 28.7% mean weight loss at the highest dose[7], and TRIUMPH-1 and TRIUMPH-2 have since been published with up to 25.0% and 18.8% mean weight loss at 80 weeks[12][13]. Lilly plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027[14]. FDA's goal for an original BLA is to act within 6 months (priority review) or 10 months (standard review) of the 60-day filing date[16], so the earliest plausible commercial launch is late 2027, and 2028 if the review is standard.

Pre-approval purchasing carries real, concrete risks that do not apply to dispensing an FDA-approved product: no FDA-reviewed safety labeling, no required REMS or post-market surveillance, no guarantee the active pharmaceutical ingredient (API) matches the Lilly-manufactured molecule that is being tested in the TRIUMPH trials, and no guarantee of sterility or correct concentration in the finished injectable. These are not hypothetical concerns; the FDA has issued explicit warnings about unapproved compounded GLP-1 products containing non-pharmaceutical-grade bulk API and patient-side dosing errors[8].

Why retatrutide isn't yet for sale through normal pharmacy channels

A drug becomes available through normal U.S. pharmacy channels (CVS, Walgreens, mail-order, telehealth) only after the manufacturer submits a marketing application to the FDA (a New Drug Application or, for retatrutide, a Biologics License Application per Lilly[14]) and the FDA approves it. Approval requires substantial-evidence demonstration of safety and efficacy from adequate and well-controlled trials, plus a manufacturing review of the production facility, labeling, and any post-market commitments. For retatrutide, Lilly says its clinical data package is complete, but it has not yet submitted the application; it plans to do so in the first quarter of 2027[14]. There is therefore no FDA-approved finished product, no FDA-cleared label, no NDC number, no wholesale distribution, and no insurance billing pathway.

Until that approval happens, the only places retatrutide legitimately exists are: (1) inside the TRIUMPH trial infrastructure as investigational product manufactured and distributed by Lilly, and (2) inside Lilly's expanded-access or compassionate-use programs if and when they open (none are publicly listed for retatrutide as of this writing).

The compounded retatrutide market — what exists and what the legality questions are

A small number of compounding pharmacies and a few telehealth providers do market compounded retatrutide directly to U.S. patients. We are not naming them and will not link to them, because the legal status of that activity is materially different from compounded semaglutide or compounded tirzepatide during their respective FDA-acknowledged shortages — and we are not in a position to make individual legal calls about who is and isn't operating within §503A.

The core regulatory question is straightforward: under §503A of the Federal Food, Drug, and Cosmetic Act, a traditional compounding pharmacy may compound a drug for an identified patient pursuant to a valid prescription only if the bulk drug substance (the active ingredient) either (a) is a component of an FDA-approved drug, (b) has an applicable USP monograph, or (c) appears on FDA's §503A bulk drug substances list[4][6]. Retatrutide does not currently satisfy any of those three conditions. There is no FDA-approved retatrutide drug for its bulk API to be a component of. There is no USP monograph for retatrutide. It is not on the §503A bulk list.

The FDA-shortage pathway — which is what made compounded semaglutide and compounded tirzepatide broadly legally available during 2023-2025 — does not apply to retatrutide. That pathway requires the drug to be on the FDA Drug Shortages list, which by definition requires an FDA-approved version to be in shortage. Without an approved brand product, there is no shortage to be on, and the §503A shortage exemption does not extend to investigational molecules.

For an FDA-approved drug, §503A permits a traditional compounding pharmacy to prepare a non-commercially available formulation (for example, an alternative concentration or a preservative-free version) for an individually identified patient based on a prescription from a licensed prescriber[4]. During an FDA-acknowledged shortage, §503A also permits compounding essentially equivalent versions of the brand product itself, which is what enabled the broad compounded semaglutide and tirzepatide markets while Wegovy, Ozempic, Zepbound, and Mounjaro were in shortage between 2022 and 2025.

For an investigational drug like retatrutide, the §503A framework is markedly stricter. Per FDA's compounding Q&A, bulk drug substances used in §503A compounding must either be a component of an FDA-approved drug, be subject to a USP/NF monograph, or appear on the §503A bulk drug substances list[6]. None of those apply to retatrutide. A compounding pharmacy that nonetheless compounds retatrutide from bulk API is operating outside the bulk-substance criterion of §503A. FDA has historically used enforcement discretion in some edge cases, but reliance on enforcement discretion is not the same as being legal — it is the agency choosing not to act today.

FDA enforcement against compounded retatrutide

FDA enforcement against compounded retatrutide is not theoretical. The agency's consumer-facing GLP-1 safety page states verbatim: “Retatrutide and cagrilintide cannot be used in compounding under federal law.”[8]

On September 9, 2025, FDA issued a coordinated enforcement sweep of more than 40 Warning Letters to telehealth-affiliated compounders and online sellers, with retatrutide among the products scrutinized. Five of those letters — to GLP-1 Solution, ASN-LABS, GenLabMeds, Amazing Meds, and MedClub by Dr. Jenn — each cite the recipient's “compounded retatrutide drug products” as failing the conditions of FDCA §§503A and 503B[9][10]. FDA's reasoning in those letters is the same in each case: retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the §503A bulks list — so drug products compounded using retatrutide are not eligible for the §503A or §503B exemptions and are being introduced into interstate commerce as unapproved new drugs.

Earlier, on December 10, 2024, FDA had issued Warning Letters to Xcel Research LLC and Swisschems, two research-peptide resellers, for selling unapproved retatrutide (also labeled LY-3437943) products in interstate commerce[11]. Those letters predate the §503A/§503B compounder sweep but established the agency's position that retatrutide- labeled products marketed “for research purposes” are still unapproved new drugs subject to FDCA enforcement.

FDA also issued a March 31, 2025 letter to the National Association of Boards of Pharmacy (NABP) stating that “Compounding prescription drug products with retatrutide is prohibited by all pharmacies compounding under either Section 503A or 503B of the Federal Food, Drug and Cosmetic Act.” This is FDA's most explicit policy statement on the question, and it predates the September 2025 enforcement sweep.

Precedent — what happened to compounded semaglutide after Wegovy supply stabilized

The compounded semaglutide market is the cleanest precedent for what is likely to happen to compounded retatrutide once the brand product is approved. From roughly mid-2022 through early 2025, semaglutide was on FDA's Drug Shortages list because of supply constraints on Wegovy and Ozempic. During that window, §503A and §503B compounders could legally produce essentially equivalent versions of semaglutide for identified patients. The result was a large and rapidly growing compounded telehealth market.

In February 2025, after Lilly resolved the tirzepatide shortage, FDA removed tirzepatide from the shortage list. FDA then removed semaglutide from the shortage list later in 2025 as Novo Nordisk supply caught up[5]. Once the shortage flag was gone, the §503A and §503B shortage exemptions no longer covered compounded versions of those products. FDA enforcement letters followed, and the broadly-available compounded semaglutide and compounded tirzepatide market shrank substantially during 2026 as the largest telehealth platforms either pivoted to brand product, exited the category, or moved into narrower personalized-dose formulations.

For retatrutide, there is no equivalent shortage pathway to begin with. Once Lilly's retatrutide is approved, compounded retatrutide will face the same regulatory pressure compounded semaglutide is facing today, with the additional layer that the pre-approval activity didn't even have a clean §503A basis to start with. See our companion explainer on compounded semaglutide bioequivalence and the §503A framework for the deeper regulatory walkthrough.

Red flags when evaluating any provider claiming to sell retatrutide

If a patient is nonetheless evaluating a provider that markets retatrutide, the following red flags meaningfully increase the risk of receiving a non-pharmaceutical-grade, non-sterile, mislabeled, or wrong-concentration product:

  • The provider does not require an individualized prescription from a licensed prescriber after an actual clinical evaluation. §503A compounding requires a valid prescription for an identified patient. Mass-marketed peptide products sold without a prescription are not §503A-compliant by definition.
  • The product is labeled “research chemical” or “not for human use”. This is a common evasion sold via gray-market peptide sites. By their own labeling, these products are not regulated drug products, are not manufactured under cGMP, and have no enforced sterility, identity, or potency standards. Several investigations have found adulterants, wrong actives, and contamination in research-peptide retatrutide products. See our companion research-chemical tirzepatide debunker for the contamination evidence on the sibling molecule.
  • No identifiable §503A or §503B compounding pharmacy is named on the label or invoice. A legitimate compounded product comes from a specific, state-licensed pharmacy (for §503A) or a FDA-registered outsourcing facility (for §503B). If you can't identify the dispensing pharmacy, you can't verify its license, complaint history, or inspection record.
  • The product ships from outside the U.S. Importing an unapproved drug for personal use is generally prohibited under §801 of the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C. §381). FDA has narrow enforcement-discretion policies for individual patient importation of foreign-approved drugs not available domestically, but those do not cover an investigational compound that has not been approved anywhere.
  • The provider claims FDA approval, FDA clearance, or FDA registration. Retatrutide is not FDA-approved. “FDA registered facility” (a registration status held by every drug manufacturer) is not the same as the product being FDA-approved.
  • No Certificate of Analysis is provided, or the CoA is generic. A legitimate compounded product's pharmacy should be able to produce a batch-specific CoA showing identity, potency, sterility, and endotoxin testing for that specific lot.

Patient-safety considerations beyond legality

Even setting aside §503A compliance, three patient-safety risks dominate the pre-approval retatrutide market and are worth considering on their own merits:

1. Bulk API identity and purity. An FDA-approved drug's API has a defined chemical identity, an approved manufacturing process, defined impurity limits, and FDA-inspected production. Bulk retatrutide sold for compounding from non-Lilly manufacturers has none of those guarantees. The peer-reviewed lipid and metabolite profile work being done on retatrutide is being done on Lilly's clinical-grade product[2]. There is no published comparability data showing that bulk-API retatrutide from third-party manufacturers is chemically identical to the Lilly molecule that produced the TRIUMPH-4 and Jastreboff phase 2 efficacy results[3].

2. Sterility of the finished injectable. Retatrutide is a subcutaneous injection. A breach in sterile manufacturing can introduce bacterial, endotoxin, or particulate contamination that produces injection-site infections at best and systemic sepsis at worst. §503B outsourcing facilities are inspected by FDA against cGMP standards; §503A traditional compounders are inspected primarily by state boards and the rigor varies; gray-market “research peptide” sellers face no enforced sterility standards at all.

3. Dosing accuracy. Retatrutide's therapeutic dose range in the TRIUMPH program is on the order of single-digit milligrams once weekly. If the labeled concentration of a compounded vial is wrong by even a factor of two, the patient is either underdosing and getting no benefit or overdosing and at substantially elevated risk of nausea, vomiting, dehydration, and the glucagon-arm side effects (heart rate elevation, slight glucose elevation) that retatrutide's mechanism creates. FDA has explicitly cited dosing errors as a recurring patient-safety problem in compounded GLP-1 products[8].

Why waiting for FDA approval is the safer path

For a patient with obesity who is asking “should I try to source retatrutide now or wait?”, the risk-benefit math heavily favors waiting in most cases. Three FDA-approved options already exist that produce clinically meaningful weight loss:

  • Semaglutide (Wegovy): mean 14.9% total body weight loss at 68 weeks in STEP 1, brand-approved, insurance-coverable, REMS-supervised. See our Foundayo vs Wegovy comparison.
  • Tirzepatide (Zepbound): mean 20.9% total body weight loss at 72 weeks in SURMOUNT-1, brand-approved, dual GLP-1/GIP mechanism.
  • Oral orforglipron (Foundayo, Eli Lilly): recently FDA-approved oral small-molecule GLP-1 receptor agonist for chronic weight management. Pivotal Phase 3 data (ATTAIN-1, Wharton 2025 NEJM, PMID 40960239) reported up to ~11% mean total body weight loss at 72 weeks. See our full GLP-1 medication reference for the current FDA-approved list.
  • Oral semaglutide (Wegovy oral 25 mg / Rybelsus, Novo Nordisk): oral GLP-1 monotherapy; oral semaglutide at 25 mg has been studied for obesity in the OASIS program with ~15–17% mean total body weight loss at 64 weeks.

All three are FDA-approved, dispensed under DEA-regulated prescriber oversight, manufactured under cGMP, covered by at least some insurance plans, and have published long-term safety data. The incremental efficacy benefit retatrutide may eventually deliver — likely on the order of an additional 5 to 10 percentage points of total body weight loss versus tirzepatide based on the phase 2 readout — needs to be weighed against the very real sourcing, sterility, dosing-accuracy, and legal risks of obtaining an unapproved compounded version today.

When retatrutide is expected to be commercially available

Based on Lilly's plan to submit a Biologics License Application in the first quarter of 2027[14] and FDA's review goals[16], the earliest plausible FDA approval is late 2027, with 2028 likely for a fully launched, insurance-billed commercial product if the review is standard. Before approval, the only legitimate access outside a trial is a narrow single-patient expanded access program, requested by a physician, for adults whose BMI remains 35 or higher despite the highest available dose of approved weight-management therapy and who have two or more serious obesity-related complications[15]. For the detailed regulatory timeline (TRIUMPH-1 and TRIUMPH-2 results, the planned Q1 2027 submission, priority-review window, and the launch logistics that follow), see our companion retatrutide approval and access timeline article. Brand pricing will not be public until launch, but is widely expected to be in the same band as Wegovy and Zepbound list price (~$1,000-$1,350/month before manufacturer savings programs and insurance).

What to do in the meantime

Practical, low-risk options if you don't want to wait until 2027 for retatrutide specifically:

  • Start on an FDA-approved GLP-1 or dual agonist now. Wegovy, Zepbound, or Foundayo each produce clinically meaningful weight loss for the majority of patients who can tolerate dose titration. The 14.9% (semaglutide) to 20.9% (tirzepatide) mean weight loss is a real, durable outcome that is unlikely to require switching to retatrutide later.
  • If you are interested in retatrutide specifically, ask your clinician about TRIUMPH trial enrollment. Several TRIUMPH sites were actively enrolling as of late 2025; enrollment status is published on ClinicalTrials.gov and updates frequently.
  • Lock in coverage paperwork now. Prior authorization for FDA-approved GLP-1 obesity drugs remains the single biggest barrier to access in 2026. Getting prior auth approved on Wegovy or Zepbound today puts you in a much stronger position to switch to retatrutide on label day-one in 2027 than starting fresh with a new clinician at that point.
  • Don't use research peptides. The documented contamination, identity, and dosing problems in gray-market peptide products are well outside the risk-benefit envelope of an FDA-approved alternative that already exists.

Frequently Asked Questions

No FDA-approved retatrutide brand product exists yet. The molecule is in late-stage Lilly clinical development, with TRIUMPH-4 reading out December 11, 2025 and TRIUMPH-1 and TRIUMPH-2 published in 2026. Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027, so there will be no FDA approval in 2026. A small compounded retatrutide market exists but sits in a regulatory gray zone because retatrutide is not on FDA's Drug Shortages list (the §503A shortage exemption requires an approved brand product to be in shortage), and the bulk active ingredient is not a component of any FDA-approved drug, has no USP monograph, and is not on FDA's §503A bulk drug substances list.
The legality is unsettled. Section 503A compounding of bulk substances requires the active ingredient to be either (a) a component of an FDA-approved drug, (b) subject to a USP monograph, or (c) on the §503A bulk drug substances list. Retatrutide currently satisfies none of those three conditions. The §503A shortage exemption that previously made compounded semaglutide and tirzepatide broadly available does not apply because there is no FDA-approved retatrutide brand product to be in shortage. Compounding pharmacies producing retatrutide from bulk API are operating outside the bulk-substance criterion of §503A. FDA has used enforcement discretion in some edge cases, but enforcement discretion is the agency choosing not to act today — it is not the same as the activity being affirmatively legal.
Compounded semaglutide was legally available from 2022 through 2025 under the §503A shortage exemption while Wegovy and Ozempic were on FDA's Drug Shortages list. When the shortage was resolved in 2025, FDA removed semaglutide from the shortage list and the §503A and §503B shortage exemptions no longer covered compounded versions. FDA enforcement letters followed and the broadly-available compounded semaglutide market shrank substantially in 2026. For retatrutide, there is no analogous shortage pathway to begin with — the activity is operating in a different regulatory posture today and will face the same enforcement pressure once Lilly's retatrutide is approved.
No individualized prescription requirement after a clinical evaluation; product labeled 'research chemical' or 'not for human use'; no identifiable §503A pharmacy or §503B outsourcing facility named on the label; shipping from outside the U.S.; the provider claims FDA approval, FDA clearance, or FDA registration of the product itself; no batch-specific Certificate of Analysis covering identity, potency, sterility, and endotoxin testing. Any one of these is a meaningful concern; multiple of them together is a near-certain indicator of gray-market, non-pharmaceutical-grade product.
No. Products marketed as 'research chemicals' or 'for laboratory use only' are by their own labeling not regulated drug products, are not manufactured under cGMP, and have no enforced sterility, identity, or potency standards. Documented investigations of gray-market GLP-1 peptide products have found adulterants, wrong actives, contamination, and dosing errors. FDA has issued explicit drug-safety communications warning patients away from these products. The risk-benefit math does not favor research-peptide retatrutide when three FDA-approved obesity drugs (Wegovy, Zepbound, Foundayo) already deliver clinically meaningful weight loss.
Not before late 2027 at the earliest. TRIUMPH-1 and TRIUMPH-2 were published in 2026, and Lilly's August 2026 earnings release says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. FDA's goal is to act within 6 months (priority review) or 10 months (standard review) after the 60-day filing period. After approval, commercial launch typically takes another 1 to 3 months for supply ramp, wholesale distribution, NDC assignment, and insurance billing setup.
Start on one of the FDA-approved options for obesity that already exist: semaglutide (Wegovy, ~14.9% mean total body weight loss at 68 weeks in STEP 1, PMID 33567185), tirzepatide (Zepbound, ~20.9% mean total body weight loss at 72 weeks in SURMOUNT-1, PMID 35658024), or oral orforglipron (Foundayo, ~11% mean total body weight loss at 72 weeks in ATTAIN-1, PMID 40960239). All are FDA-approved, cGMP-manufactured, prescriber-supervised, and at least partially insurance-coverable. Lock in prior authorization paperwork now — that is the biggest practical barrier to access in 2026, and getting approved on a current GLP-1 puts you in a much stronger position to switch to retatrutide on label day-one once it is approved.
No. U.S. commercial insurance and Medicare do not cover compounded medications outside narrow exceptions (specific allergy customizations, hospital-administered §503B products with HCPCS codes). Compounded retatrutide is universally cash-pay, which is one of the reasons the per-month price patients see from compounded providers can look attractive relative to brand-list Wegovy or Zepbound — but that comparison only matters if your insurance isn't covering the brand product in the first place. Run the prior-authorization process on Wegovy, Zepbound, or Foundayo first before assuming you need to pay cash for any GLP-1.
§503A traditional compounding pharmacies prepare medications for individually identified patients based on a specific prescription from a licensed prescriber; they are regulated primarily by state pharmacy boards. §503B outsourcing facilities can compound in bulk without patient-specific prescriptions for hospitals and clinics, but they are FDA-registered, inspected against cGMP standards, and limited to bulk substances on FDA's §503B bulk drug substances list. Neither §503A nor §503B currently has a clean regulatory pathway for retatrutide because the bulk ingredient is neither a component of an approved drug, on the §503A bulk list, on the §503B bulk list, nor subject to a USP monograph.
No — but not because it is available over the counter. There is no FDA-approved retatrutide product for any clinician to legally prescribe or any pharmacy to dispense, because retatrutide is still investigational and exists legitimately only inside Lilly's TRIUMPH clinical trials. Any website telling you that you can get a 'prescription' for retatrutide, or that no prescription is needed, is marketing an unapproved new drug outside the legal supply chain. If you want a prescribed medication for weight loss today, ask a licensed clinician about FDA-approved semaglutide (Wegovy) or tirzepatide (Zepbound), which can be legitimately prescribed, dispensed, and monitored.
It depends entirely on which peptide and which seller. FDA-approved peptide medications such as semaglutide and tirzepatide can be obtained legally online only through a licensed pharmacy against a valid prescription from a clinician who has actually evaluated you. 'Research peptides' like retatrutide, sold from chemistry-supply sites labeled 'for research use only, not for human consumption,' are a different category entirely: buying one to inject yourself means self-administering an unapproved new drug of unverified identity, purity, dose, and sterility, with no medical oversight and no recourse if something goes wrong. That 'research use only' label is the seller's liability shield, not a sign the product is safe or legal for you to use — the safe, legal path is a licensed prescriber and an FDA-approved product.

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

References

  1. 1.Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026. PMID: 41090431.
  2. 2.Pearson MJ, Willency JA, Lin Y, et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026. PMID: 42135195.
  3. 3.Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.
  4. 4.U.S. Food and Drug Administration. Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA Compounding Quality Center of Excellence. 2024. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
  5. 5.U.S. Food and Drug Administration. FDA Drug Shortages: Resolved Shortage of Semaglutide Injection Products. FDA Drug Shortages Database. 2026. https://www.accessdata.fda.gov/scripts/drugshortages/
  6. 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (compounders may not compound a drug that is essentially a copy of an approved drug; bulk drug substances must appear on the §503A bulk list or be a component of an FDA-approved drug). FDA.gov. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  7. 7.Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4 topline). Lilly Investor Press Release, December 11, 2025. 2025. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
  8. 8.U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Verbatim from FDA's consumer safety page: "Retatrutide and cagrilintide cannot be used in compounding under federal law. ... FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled 'for research purposes' or 'not for human consumption.'" FDA.gov Drug Safety Communication. 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  9. 9.U.S. Food and Drug Administration. Warning Letter to GLP-1 Solution (715883, September 9, 2025). Cites "Failure to Meet the Conditions of Sections 503A and 503B. Your compounded retatrutide drug products fail to meet the conditions of sections 503A and 503B. ... Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list." FDA Warning Letters Database. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
  10. 10.U.S. Food and Drug Administration. Warning Letter to ASN-LABS (716459, September 9, 2025). Cites compounded retatrutide drug products as unapproved new drugs in violation of FDCA §§505(a), 502(f)(1), 301(a), and 301(d). FDA Warning Letters Database. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-716459-09092025
  11. 11.U.S. Food and Drug Administration. Warning Letter to Xcel Research LLC (694608, December 10, 2024). Cites "RETA" (Retatrutide) products as unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of FDCA §§505(a) and 301(d). FDA Warning Letters Database. 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024
  12. 12.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  13. 13.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  14. 14.Eli Lilly and Company. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit). U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
  15. 15.Eli Lilly and Company. Pre-approval Expanded Access of Retatrutide (LY3437943) (NCT07629401). ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07629401
  16. 16.U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027 (PDUFA VII commitment letter). FDA.gov. 2022. https://www.fda.gov/media/151712/download

Retatrutide and kidney protection: Phase 2 post-hoc evidence and TRANSCEND-CKD

Retatrutide is investigational and not FDA-approved. Heerspink 2025 Kidney Int Rep post-hoc Phase 2: 12 mg cut UACR -37% at 36 wk in T2D; 8/12 mg raised eGFR +5.3/+8.5 mL/min/1.73 m2 in obesity at 48 wk. TRANSCEND-CKD Phase 2b (n=146) results not yet published.

19 min read

Retatrutide for type 2 diabetes: TRIUMPH-2 Phase 3 results and Phase 2 evidence

Retatrutide is investigational and not FDA-approved. In TRIUMPH-2 (Lancet 2026, n=1,152, placebo-controlled), adults with obesity and T2D lost 18.8% of body weight on 12 mg vs 5.1% on placebo at 80 weeks. Lilly plans an FDA filing in Q1 2027.

18 min read

Retatrutide Dosage: TRIUMPH-1 Escalation Ladder + Clinical Evidence

Retatrutide (Eli Lilly LY3437943) is dosed weekly subcutaneously and escalated 2 mg to 4 mg to 6 mg to 9 mg to 12 mg in 4-week steps in TRIUMPH-1 — about 20 weeks to reach the max 12 mg dose. Pre-approval; final FDA-label dosing pending.

12 min read

Are Peptides Legal? 2026 Rules for Compounded vs Research Peptides

FDA-approved peptide drugs are legal by prescription. A draft October 2026 HHS policy says HHS does not intend to enforce against 503A compounding of six peptides, including BPC-157 and TB-500, under ten conditions. Research-chemical peptides are still not legal for human use.

12 min read

HHS Peptide Compounding Policy (2026): What It Allows for BPC-157 and 5 Others

In a draft, non-binding policy announced October 28, 2026, HHS says it does not intend to bring enforcement action against 503A pharmacies that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon if ten conditions are met. Only single-ingredient products qualify.

11 min read

How to Get a BPC-157 Prescription in 2026: 503A Pharmacy Steps and Red Flags

How to get BPC-157 online in 2026 under the draft HHS 503A policy: who can prescribe and compound it, the questions to ask a pharmacy (COA, single ingredient, label, syringe), research-chemical red flags, and what the evidence shows.

9 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $139/mo

4-month plan rate

Get started →
7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Read full review →

From $149/mo

+ required membership

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $59/mo

+ required membership

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →